Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY GroupLJUIF 88 Debt-to-Equity is 0.55 as of Dec. 2025, which is 10% above its 10-year median of 0.50. GuruFocus rates LJUIF with a GF Score™ of 88/100 and a GF Value™ of $0.45. The stock has 7 warning signs investors should review. Among 810 Drug Manufacturers companies, SSY Group ranks worse than 71.98% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for SSY Group's Debt-to-Equity or its related term are showing as below:
LJUIF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.34 Med: 0.5 Max: 0.59
Current: 0.55
During the past 13 years, the highest Debt-to-Equity Ratio of SSY Group was 0.59. The lowest was 0.34. And the median was 0.50.
LJUIF's Debt-to-Equity is ranked worse than 71.98% of 810
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs LJUIF: 0.55
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
SSY Group Debt-to-Equity Related Terms
SSY Group Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for SSY Group's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where SSY Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (LJUIF) has a Debt-to-Equity of 0.55 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SSY Group and its competitors. This is 10% above median its historical median of 0.50. Over the past decade, SSY Group's Debt-to-Equity has ranged from 0.34 to 0.59. According to the industry distribution chart, SSY Group ranks #583 out of 810 companies in the Drug Manufacturers industry, placing it in the top 72%.
Is SSY Group's Debt-to-Equity too high?
SSY Group's current Debt-to-Equity of 0.55 is 10% above median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 0.59. The Drug Manufacturers industry median Debt-to-Equity is 0.28. SSY Group's value of 0.55 is 96.4% above this industry median. Based on the distribution chart, SSY Group ranks #583 out of 810 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, SSY Group has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does SSY Group's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #583 out of 810 companies for Debt-to-Equity. This places SSY Group in the lower half of its industry. The industry median Debt-to-Equity is 0.28. SSY Group's value of 0.55 is 96.4% above this benchmark. Historically, SSY Group's own Debt-to-Equity has ranged from 0.34 to 0.59 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 0.28, SSY Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current Debt-to-Equity of 0.55 is 96.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current Debt-to-Equity is 0.55, which is 10% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
SSY Group (LJUIF) has a current Debt-to-Equity of 0.55. The stock's GF Value™ is $0.45, compared to a current price of $0.40 — trading 10.5% below its estimated fair value. The current Debt-to-Equity is 0.55, which is 10% above median its 10-year median of 0.50 and 96.4% above the Drug Manufacturers industry median of 0.28. SSY Group's overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For SSY Group (LJUIF), the current Debt-to-Equity is 0.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (LJUIF) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of $0.40 is trading 10.5% below its estimated GF Value™ of $0.45.
Key valuation signals for LJUIF:
Debt-to-Equity: 0.55 (10% above median its 10-year median of 0.50)
GF Value™: $0.45 vs. price of $0.40 (10.5% below fair value)
Industry Position: 96.4% above the Drug Manufacturers median (#583 of 810)
No single metric tells the full story. See the LJUIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
88GF Score
Get the complete analysis for LJUIF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LJUIF has been successfully added to your 
